Last reviewed · How we verify
Rifapentine daily
At a glance
| Generic name | Rifapentine daily |
|---|---|
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Shorter and Safer Treatment Regimens for Latent TB (PHASE2, PHASE3)
- A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (PHASE1, PHASE2)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts (PHASE3)
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifapentine daily CI brief — competitive landscape report
- Rifapentine daily updates RSS · CI watch RSS
- Yale University portfolio CI